Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono | 14 | FierceBiotech | ||
08.05. | Ono Pharmaceutical reports FY results | 9 | Seeking Alpha | ||
29.04. | Ono Pharma lays off 83 staffers at Cambridge site | 4 | FierceBiotech | ||
12.03. | Ono earmarks $940m to gain rare blood cancer therapy from Ionis | 7 | Pharmaceutical Technology | ||
ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
12.03. | Ono pays $280M to license Ionis rare disease drug | 3 | BioPharma Dive | ||
12.03. | Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal | 2 | Benzinga.com | ||
12.03. | Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono | 5 | Zacks | ||
12.03. | Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer | 4 | FierceBiotech | ||
04.03. | DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight | 761 | PR Newswire | On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places... ► Artikel lesen | |
04.03. | DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight | 844 | PR Newswire | On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places... ► Artikel lesen | |
18.02. | Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor | 7 | MedCity News | ||
17.02. | Ono's TGCT therapy wins FDA approval, challenging Daiichi Sankyo | 18 | Pharmaceutical Technology | ||
17.02. | Ono poised to join Daiichi in TGCT market after FDA nod | 7 | pharmaphorum | ||
03.02. | Ono Pharmaceutical GAAP EPS of ¥162.87, revenue of ¥374.56B; reaffirms FY outlolok | 20 | Seeking Alpha | ||
09.11.24 | Fate Therapeutics, Inc.: Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual ... | 306 | GlobeNewswire (Europe) | Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable... ► Artikel lesen | |
07.10.24 | Kinaxis Inc.: Kinaxis unterstützt das Lieferkettenmanagement von Ono Pharmaceutical | 470 | Business Wire | Kinaxis stellt Plattform für die End-to-End-Lieferkettenorchestrierung zur Unterstützung des weiteren globalen Wachstums von Ono Pharmaceutical bereit Kinaxis Inc. (TSX:KXS), ein Weltmarktführer... ► Artikel lesen | |
12.09.24 | Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical | 498 | Business Wire | - Turbine has successfully completed the first phase of its oncology target identification and validation collaboration with Ono - Ono's selection of multiple targets identified using Turbine's... ► Artikel lesen | |
31.07.24 | EQS-News: Systasy Bioscience GmbH: Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical | 444 | EQS Group (EN) | EQS-News: Systasy Bioscience GmbH
/ Key word(s): Agreement
Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical
31.07.2024 / 09:00 CET/CEST
The... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GILEAD SCIENCES | 98,80 | +0,13 % | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
CANOPY GROWTH | 1,498 | +0,67 % | Canopy Growth has price target chopped at Roth | ||
MERCK & CO | 69,30 | 0,00 % | Merck & Co: Heiße Gerüchte - mit Wurzeln nach Darmstadt | Das Übernahmekarussell hat im Biotechnologie-Sektor zuletzt wieder merklich an Dynamik gewonnen. Erst am gestrigen Montag sorgte der Pharma-Konzern Sanofi mit der angestrebten Übernahme vom ehemaligen... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
JAGUAR HEALTH | 3,885 | -2,88 % | Jaguar Health, Inc.: Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 243,70 | -0,12 % | Citizens JMP behält positive Einschätzung für Madrigal-Aktie bei | ||
IQVIA | 132,90 | -0,56 % | Iqvia-Aktie: Kurs steigt nur geringfügig (129,8960 €) | Der Kurs der dem Anteilsschein von Iqvia kommt kaum von der Stelle. Die Aktie kostete zuletzt 148,64 US-Dollar. Kaum verändert im Vergleich zu der Schlussnotierung vom Vortag zeigt sich derzeit der... ► Artikel lesen | |
AZENTA | 24,800 | -0,80 % | Azenta, Inc.: Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development | Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
BURLINGTON, Mass., ... ► Artikel lesen | |
ALMIRALL | 11,120 | 0,00 % | ALMIRALL, S.A.: Information on dividend | ||
PROTHENA | 4,700 | -1,26 % | Prothena Corporation plc: Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint | Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints
Birtamimab development will be discontinued, including stopping the open label extension... ► Artikel lesen | |
PETIQ | 28,400 | 0,00 % | PetIQ, Inc.: PetIQ Names Camillo Pane as Chief Executive Officer | Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading... ► Artikel lesen | |
FUJI PHARMA | 7,700 | -1,28 % | Dividendenbekanntmachungen (28.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC ADR US00108N1000 0,3716 USD 0,3442 EUR ACOM CO LTD JP3108600002 7 JPY 0,0429 EUR ADVANEX INC JP3213400009 20... ► Artikel lesen | |
FINANCIERE DE TUBIZE | 129,60 | -0,46 % | Dividendenbekanntmachungen (30.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AG MORTGAGE INVESTMENT TRUST INC US0012285013 0,2 USD EUR ALLIED PROPERTIES REAL ESTATE INVESTMENT ... CA0194561027 0,15 CAD 0... ► Artikel lesen | |
BAYER | 26,435 | +0,02 % | Bayer, Vidac Pharma, Evotec - schnappen Sie sich den 866 Milliarden Onkologie Jackpot | Die Onkologie erlebt eine beispiellose Revolution. Mit prognostizierten 866 Mrd. USD Marktvolumen bis 2034 und 11 % Jahreswachstum treiben KI-gestützte Diagnosen, personalisierte Gentherapien und Präzisionsmedizin... ► Artikel lesen | |
MERCK KGAA | 115,20 | -0,17 % | Aktie von Merck legt um 0,83 Prozent zu (116,00 €) | Das Wertpapier von Merck notiert heute fester. Die Aktie kostete zuletzt 116,00 Euro. Heute hat sich am deutschen Aktienmarkt die Merck-Aktie zwischenzeitlich um 0,83 Prozent verteuert. Der Kurs des... ► Artikel lesen |